More on GMAB

- Summary
- Chart
- Profile
- Historical

Data

- Earnings
- Ratings (7.5 Score)

Upcoming Events

- Earnings (11/6/26 *Est.)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Genmab A/S (NQ:GMAB)
Delayed: 31.13 +1.30 (4.36%)
Prev. Close $29.83  
Open$31.44 
52 Wk High$ 
52 Wk Low$ 
Day High$31.79 
Day Low$30.92 
P/E N/A  
EPS$ 
Volume2,576,585 

Friends, Peers and Foes (?): GNMSF, 0MGB, GEN:DC, MRUS, GERN (more...)

Aug 7, 2026 04:37 AM Genmab A/S (GEN:DC) (GMAB) PT Raised to DKK2,700 at UBS
Aug 6, 2026 01:20 PM Genmab stock falls despite H1 revenue rise
Aug 6, 2026 11:09 AM Form 6-K GENMAB A/S For: Jun 30
Aug 6, 2026 11:02 AM Genmab revenue rises 25% in first half of 2026, guidance raised
Aug 6, 2026 11:01 AM Genmab Announces Financial Results for the First Half of 2026
Jul 23, 2026 04:00 PM Genmab and AbbVie say epcoritamab trial missed U.S. survival goal
Jul 23, 2026 04:00 PM Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Jul 22, 2026 06:15 AM TD Cowen Upgrades Genmab A/S (GMAB) to Buy
Jul 15, 2026 07:22 AM Form 6-K GENMAB A/S For: Jul 15
Jul 15, 2026 06:23 AM Darzalex global sales reach $4.2 billion in Q2 2026
View All Articles

Entities mentioned with GMAB

View All Entities